Cargando…

Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma

INTRODUCTION: Renal cell carcinoma has been considered radioresistant. Recently, several studies have reported the efficacy of combination therapy using radiotherapy and immune checkpoint inhibitors. CASE PRESENTATION: In 1999, a 56‐year‐old woman underwent left nephrectomy (clear cell carcinoma, pT...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakajima, Nobuyuki, Kano, Tatsuo, Oda, Kazuya, Uchida, Takato, Otaki, Tatsuya, Nagao, Kentaro, Shimizu, Yuki, Kawakami, Masayoshi, Kim, Hakushi, Nitta, Masahiro, Hasegawa, Masanori, Kawamura, Yoshiaki, Miyajima, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469856/
https://www.ncbi.nlm.nih.gov/pubmed/32914080
http://dx.doi.org/10.1002/iju5.12195
Descripción
Sumario:INTRODUCTION: Renal cell carcinoma has been considered radioresistant. Recently, several studies have reported the efficacy of combination therapy using radiotherapy and immune checkpoint inhibitors. CASE PRESENTATION: In 1999, a 56‐year‐old woman underwent left nephrectomy (clear cell carcinoma, pT1bN0M0). Seventeen years postoperatively, recurrence in the left lung hilum was observed. Despite administration of three molecular target drugs, all treatments were terminated due to adverse events. Nivolumab was initiated in December 2016. In August 2017, subcutaneous and lung metastases were observed. Moreover in January 2018, right renal metastasis was noted. After 22 cycles of nivolumab treatment, metastasis in the iliac bone was observed, and the patient was subjected to conventional palliative external beam radiation therapy. Five months after radiotherapy, there was significant reduction in multiple metastases. Here, we reported the case presenting with possible abscopal effect. CONCLUSION: Radiotherapy combined with immune checkpoint inhibitors may induce systemic effects against metastatic renal carcinoma.